US respiratory industry caught out by CMS' baffling long-term oxygen policy
This article was originally published in Clinica
The US Centers for Medicare and Medicaid Services (CMS) unexpected announcement that it will reconsider its 12 year-old coverage policy for home oxygen use is baffling the respiratory industry. The agency's reconsideration plans, announced last month with little explanation, sparked considerable discussion last week, when delegates met in Denver for the 6th Consensus Conference on Long Term Oxygen Therapy.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.